CCL3 and diffuse large B-cell lymphoma: The data signify a close association of EBNA2-induced CCL3 and CCL4 upregulation with Btk and NF-κB activation pathways, supporting the potential utility of Btk and/or NF-κB as promising targets to overcome chemoresistance of EBV-positive DLBCL.